Search

Your search keyword '"Tokgözoğlu, Lale"' showing total 591 results

Search Constraints

Start Over You searched for: Author "Tokgözoğlu, Lale" Remove constraint Author: "Tokgözoğlu, Lale"
591 results on '"Tokgözoğlu, Lale"'

Search Results

2. Diagnosis and Treatment Patterns of Chronic Thromboembolic Pulmonary Hypertension in Russia, Kazakhstan, Turkey, Lebanon, and Saudi Arabia: A Registry Study

3. Contributors

4. Statins

5. DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases

9. Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society

12. Baseline Characteristics and Clinical Insights from the ARTEMIS Registry: A Comprehensive Study of Peripartum Cardiomyopathy in Türkiye.

13. Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract

15. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

17. Mental status and physical activity in patients with homozygous familial hypercholesterolemia: A subgroup analysis of a nationwide survey (A-HIT1 registry)

18. Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement

19. Current barriers and recommendations on the diagnosis of transthyretin amyloid cardiomyopathy: a Delphi study

20. World Heart Federation Roadmap for Secondary Prevention of Cardiovascular Disease: 2023 Update

21. Incidence of cardiovascular events in patients with stabilized coronary heart disease : the EUROASPIRE IV follow-up study

22. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

24. Residual vascular risk in diabetes – Will the SPPARM alpha concept hold the key?

25. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries

33. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

34. Disconnect between triglyceride reduction and cardiovascular outcomes: lessons from the PROMINENT and CLEAR Outcomes trials.

35. Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis Society

39. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement

40. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance

41. From the EAS:* frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society

42. Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society

45. Atherosclerosis

46. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

47. Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis Society.

48. Evaluation of lipoprotein(a) in the prevention and management of atherosclerotic cardiovascular disease: A survey among the Lipid Clinics Network

49. Lipid Modification to Reduce Cardiovascular Risk in Secondary Prevention Patients with Special Emphasis on PCSK9 Inhibitor Requirement: An Analysis Based on Delphi Panel Approach

50. In memoriam: Akira Endo.

Catalog

Books, media, physical & digital resources